Li Xin-Yu, Zhong Chang-Ying, Xu Hui-Xian
Institute of Rehabilitation and Health Care, Department of Rehabilitation and Traditional Chinese Medicine, Hunan Traditional Chinese Medical College, Zhuzhou, Hunan, China.
Otolaryngology Department, Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, Hunan, China.
Front Oncol. 2025 Jan 17;14:1529136. doi: 10.3389/fonc.2024.1529136. eCollection 2024.
Many results suggested that chemotherapy cannot provide survival benefit for stage II nasopharyngeal carcinoma. It remained unclear whether the efficacy of chemotherapy differed in non-Asian populations.
It was designed to analyze the effect of chemotherapy for Asian and non-Asian patients with stage II nasopharyngeal carcinoma.
Patients were collected using the SEER program. The variables included age, sex, race, marital status, survival time, survival status, TNM stage, radiation and chemotherapy. Utilizing the Rstudio (version: 2024.4.1.748) and R (version: 4.4.1), backward elimination method was employed to screen the variables and multivariate Cox regression analyses was conducted on the screened variables. Kaplan-Meier method was utilized to analyze the survival of sub-stages and different races with T1-2N1M0 stage. The log-rank test was used for statistical analysis.
1539 patients were collected. Chemotherapy was statistically significant, with a hazard ratio (HR) of 0.64, P=0.003 in stage II patients. The HR for radiation was 0.33, P<0.001. Chemotherapy didn't improve cancer-specific survival for patients with T2N0M0 stage. Asian and non-Asian races showed no difference in cancer-specific survival in T2N0M0 stage with HR of 1.85, P=0.13. For patients with T1-2N1M0 stage, chemotherapy improved cancer-specific survival with a HR of 0.53, P<0.001. No significant difference was in the Kaplan-Meier analysis between the two sub-stages (P=0.065). In T1-2N1M0 stage, multivariate Cox regression analysis for Asian race indicated that chemotherapy didn't improve cancer-specific survival with a HR of 0.64, P=0.190. For non-Asian race, chemotherapy was found to improve cancer-specific survival, with a HR of 0.51, P<0.001. The Kaplan-Meier analysis of Asian and non-Asian patients with T1-2N1M0 stage exhibited significant differences (P<0.0001).
Chemotherapy is correlated with the cancer-specific survival in non-Asian patients with T1-2N1M0-stage nasopharyngeal carcinoma, but not in Asian patients at the same stage. For patients with the T2N0M0 stage, chemotherapy is not correlated with the cancer-specific survival rate, regardless of ethnicity.
许多研究结果表明，化疗无法为II期鼻咽癌患者带来生存获益。目前尚不清楚化疗疗效在非亚洲人群中是否存在差异。
分析化疗对亚洲和非亚洲II期鼻咽癌患者的疗效。
使用监测、流行病学和最终结果（SEER）计划收集患者。变量包括年龄、性别、种族、婚姻状况、生存时间、生存状态、TNM分期、放疗和化疗。利用Rstudio（版本：2024.4.1.748）和R（版本：4.4.1），采用向后剔除法筛选变量，并对筛选出的变量进行多因素Cox回归分析。采用Kaplan-Meier法分析T1-2N1M0期亚分期和不同种族的生存率。采用对数秩检验进行统计学分析。
共收集1539例患者。在II期患者中，化疗具有统计学意义，风险比（HR）为0.64，P=0.003。放疗的HR为0.33，P<0.001。化疗未改善T2N0M0期患者的癌症特异性生存率。在T2N0M0期，亚洲和非亚洲种族的癌症特异性生存率无差异，HR为1.85，P=0.13。对于T1-2N1M0期患者，化疗改善了癌症特异性生存率，HR为0.53，P<0.001。两个亚分期之间的Kaplan-Meier分析无显著差异（P=0.065）。在T1-2N1M0期，亚洲种族的多因素Cox回归分析表明化疗未改善癌症特异性生存率，HR为0.64，P=0.190。对于非亚洲种族，发现化疗可改善癌症特异性生存率，HR为0.51，P<0.001。T1-2N1M0期亚洲和非亚洲患者的Kaplan-Meier分析显示存在显著差异（P<0.0001）。
化疗与非亚洲T1-2N1M0期鼻咽癌患者的癌症特异性生存相关，但与同期亚洲患者无关。对于T2N0M0期患者，无论种族如何，化疗与癌症特异性生存率均无关。
